Goldman Sachs Incyte Corporation Is A Top Growth Investor Stock
| INCY Stock | USD 63.81 0.50 0.79% |
Slightly above 52% of Incyte's investor base is interested to short. The analysis of overall sentiment of trading Incyte stock suggests that many investors are impartial at this time. Incyte's investing sentiment can be driven by a variety of factors including economic data, Incyte's earnings reports, geopolitical events, and overall market trends.
With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future of artificial intelligence, the Federal Reserves interest rate cut cycle, and an economy with ...
Read at insidermonkey.com
 |
Incyte Fundamental Analysis
We analyze Incyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Incyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Incyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Incyte is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Incyte Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Incyte stock to make a market-neutral strategy. Peer analysis of Incyte could also be used in its relative valuation, which is a method of valuing Incyte by comparing valuation metrics with similar companies.
Peers
Incyte Related Equities
| SRPT | Sarepta Therapeutics | 3.29 | ||||
| ARWR | Arrowhead Pharmaceuticals | 2.41 | ||||
| HRMY | Harmony Biosciences | 2.40 | ||||
| ALNY | Alnylam Pharmaceuticals | 2.30 | ||||
| RARE | Ultragenyx | 1.63 | ||||
| IONS | Ionis Pharmaceuticals | 1.40 | ||||
| APLS | Apellis Pharmaceuticals | 1.26 | ||||
| DNLI | Denali Therapeutics | 0.94 | ||||
| ARGX | Argenx NV | 0.69 | ||||
| AXSM | Axsome Therapeutics | 0.29 | ||||
| BMRN | Biomarin Pharmaceutical | 0.24 | ||||
| UTHR | United Therapeutics | 0.01 | ||||
| FOLD | Amicus Therapeutics | 0.16 | ||||
| ACAD | ACADIA Pharmaceuticals | 1.21 |
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.